McGuire, found that oral semaglutide reduced major adverse cardiovascular events (MACE) to 3.1 events per 100 person-years, compared to 3.7 events in the placebo group a 14% reduction (HR 0.86) over a median follow-up of 49.5 months
Those who complained of gastrointestinal adverse effects were also more likely to discontinue use as well as those who lost more weight
Katie Friday Event Co-Chairs
Whether it's due to a busy schedule, the high price, or cravings
Without adequate protein intake, the body simply cannot produce enough keratin to maintain normal hair growth
Blog Editors Recent Updates Executive Order 14321 at One Year: Civil Commitment Policy Shifts and Provider Impact Watch: FDAs 2026 Enforcement Priorities: What In-House Counsel Must Know Thought Leaders in Health Law The Future of 340B: New Bills Offer Competing Solutions to Modernize the 340B Drug Discount Program "Enough Is Enough": HHS-OIG Freezes Funds for New York Medicaid Fraud Control Unit, Effective July 1 Straight From the Source: AHLA Annual Meeting Highlights Fraud and Abuse Enforcement Efforts in 2026 and Beyond
